241 related articles for article (PubMed ID: 36768928)
21. The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth.
Gualtieri A; Bianconi V; Renzini A; Pieroni L; Licursi V; Mozzetta C
Cell Rep; 2022 Aug; 40(9):111267. PubMed ID: 36044855
[TBL] [Abstract][Full Text] [Related]
22. Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.
Jacob AG; O'Brien D; Singh RK; Comiskey DF; Littleton RM; Mohammad F; Gladman JT; Widmann MC; Jeyaraj SC; Bolinger C; Anderson JR; Barkauskas DA; Boris-Lawrie K; Chandler DS
Neoplasia; 2013 Sep; 15(9):1049-63. PubMed ID: 24027430
[TBL] [Abstract][Full Text] [Related]
23. [Rhabdomyosarcoma lysis by T cells expressing a human autoantibody based chimeric receptor targeting the fetal acetylcholine receptors].
Gattenlöhner S
Verh Dtsch Ges Pathol; 2006; 90():264-76. PubMed ID: 17867605
[TBL] [Abstract][Full Text] [Related]
24. Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma.
Fiorito E; Szybowska P; Haugsten EM; Kostas M; Øy GF; Wiedlocha A; Singh S; Nakken S; Mælandsmo GM; Fletcher JA; Meza-Zepeda LA; Wesche J
Br J Cancer; 2022 Nov; 127(11):1939-1953. PubMed ID: 36097178
[TBL] [Abstract][Full Text] [Related]
25. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
26. Establishment of 6 pediatric rhabdomyosarcoma patient's derived xenograft models closely recapitulating patients' tumor characteristics.
Gasparini P; Casanova M; Centonze G; Borzi C; Bergamaschi L; Collini P; Testi A; Chiaravalli S; Massimino M; Sozzi G; Ferrari A; Moro M
Tumori; 2023 Jun; 109(3):314-323. PubMed ID: 36114629
[TBL] [Abstract][Full Text] [Related]
27. Rapid liposomal formulation for nucleolin targeting to rhabdomyosarcoma cells.
Dzhumashev D; Anton-Joseph S; Morel VJ; Timpanaro A; Bordon G; Piccand C; Aleandri S; Luciani P; Rössler J; Bernasconi M
Eur J Pharm Biopharm; 2024 Jan; 194():49-61. PubMed ID: 38029941
[TBL] [Abstract][Full Text] [Related]
28. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
29. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
Kang Z; Chen JJ; Yu Y; Li B; Sun SY; Zhang B; Cao L
Clin Cancer Res; 2011 May; 17(10):3181-92. PubMed ID: 21385927
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target.
Shields CE; Potlapalli S; Cuya-Smith SM; Chappell SK; Chen D; Martinez D; Pogoriler J; Rathi KS; Patel SA; Oristian KM; Linardic CM; Maris JM; Haynes KA; Schnepp RW
Mol Oncol; 2021 Aug; 15(8):2156-2171. PubMed ID: 33523558
[TBL] [Abstract][Full Text] [Related]
31. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.
Makawita S; Ho M; Durbin AD; Thorner PS; Malkin D; Somers GR
Pediatr Dev Pathol; 2009; 12(2):127-35. PubMed ID: 18788888
[TBL] [Abstract][Full Text] [Related]
32. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
[TBL] [Abstract][Full Text] [Related]
33. Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma.
Tombolan L; Poli E; Martini P; Zin A; Millino C; Pacchioni B; Celegato B; Bisogno G; Romualdi C; Rosolen A; Lanfranchi G
BMC Cancer; 2016 Nov; 16(1):886. PubMed ID: 27842508
[TBL] [Abstract][Full Text] [Related]
34. CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway.
Hernandez KC; Shah AM; Lopez VA; Tagliabracci VS; Chen K; Xu L; Bassel-Duby R; Olson EN; Liu N
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2315925121. PubMed ID: 38227654
[TBL] [Abstract][Full Text] [Related]
35. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
36. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
37. Epigenetically upregulated GEFT-derived invasion and metastasis of rhabdomyosarcoma via epithelial mesenchymal transition promoted by the Rac1/Cdc42-PAK signalling pathway.
Liu C; Zhang L; Cui W; Du J; Li Z; Pang Y; Liu Q; Shang H; Meng L; Li W; Song L; Wang P; Xie Y; Wang Y; Liu Y; Hu J; Zhang W; Li F
EBioMedicine; 2019 Dec; 50():122-134. PubMed ID: 31761617
[TBL] [Abstract][Full Text] [Related]
38. Variation in cadherins and catenins expression is linked to both proliferation and transformation of Rhabdomyosarcoma.
Charrasse S; Comunale F; Gilbert E; Delattre O; Gauthier-Rouvière C
Oncogene; 2004 Mar; 23(13):2420-30. PubMed ID: 14691446
[TBL] [Abstract][Full Text] [Related]
39. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.
Ouchi K; Miyachi M; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Iehara T; Hosoi H
Cancer Cell Int; 2020; 20():192. PubMed ID: 32489328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]